SCHEMBL328489

SCHEMBL328489

CP1(=O)OCCSSCCO1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17146589 0.78
SCHEMBL787556 0.78
SCHEMBL3416918 0.73
SCHEMBL11999097 0.72
SCHEMBL19397856 0.71
SCHEMBL19397853 0.71
SCHEMBL13020544 0.62
SCHEMBL2123909 0.59
SCHEMBL19307816 0.57
SCHEMBL8383920 0.57

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11351183-B2 Use of thyroid beta-agonists VIKING THERAPEUTICS, INC. (US) 2022-06-07 US disclosed
US-10925885-B2 Thyromimetics for the treatment of fatty liver diseases METABASIS THERAPEUTICS, INC. (US) 2021-02-23 US disclosed
US-20200338098-A1 Conjoint Therapies with Inhibitors of Glucose Production VIKING THERAPEUTICS, INC. 2020-10-29 US disclosed
US-20190321379-A1 USE OF THYROID BETA-AGONISTS CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-10-24 US disclosed
US-20190134069-A1 USE OF THYROID BETA-AGONISTS VIKING THERAPEUTICS, INC. 2019-05-09 US disclosed
US-20190083515-A1 THYROMIMETICS FOR THE TREATMENT OF FATTY LIVER DISEASES CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-03-21 US disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 US disclosed
US-20170112864-A1 Thyromimetics for the Treatment of Fatty Liver Diseases METABASIS THERAPEUTICS, INC. (US) 2017-04-27 US disclosed
US-20170112864-A1 Thyromimetics for the Treatment of Fatty Liver Diseases METABASIS THERAPEUTICS, INC. (US) 2017-04-27 US disclosed
US-20080004226-A1 Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes METABASIS THERAPEUTICS, INC. (US) 2008-01-03 US disclosed
US-20080004226-A1 Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes METABASIS THERAPEUTICS, INC. (US) 2008-01-03 US disclosed
US-7312219-B2 Heteroaromatic inhibitors of fructose 1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-12-25 US disclosed
US-7312219-B2 Heteroaromatic inhibitors of fructose 1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-12-25 US disclosed
US-7285543-B2 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-23 US disclosed
US-7285543-B2 Purine inhibitors of fructose-1,6-bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-23 US disclosed
US-20070232571-A1 Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-04 US disclosed
US-20070232571-A1 Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase METABASIS THERAPEUTICS, INC. (US) 2007-10-04 US disclosed
US-20070099851-A1 Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders LINN GREGORY S 2007-05-03 US disclosed
US-20070099851-A1 Stable analogues of ribose-1-phosphate and methods for treating diabetes and other metabolic disorders LINN GREGORY S 2007-05-03 US disclosed